The extensive phenotyping in BWHHS makes it an important study in genetic epidemiology collaborations both nationally and internationally.
This project investigates the genetic determinants of cardiovascular risk factors as well as allowing large-scale Mendelian randomization studies to investigate the causal role of emerging risk factors.
The BWHHS is one of many population based prospective studies that
contributes to the UCL-LSHTM-Edinburgh-Bristol (UCLEB) metabochip consortium.
The consortium works to explain the precise relationship between the genes
and biological changes that precede CVD.
The aim is to understand the population impact of genetic variation on stratification, prediction and causal analysis, and to use this to help design new preventative treatments.
COPD-Exome Chip Consortium
consortium aims to identify the genetic determinants of Chronic Obstructive
Pulmonary Disease (COPD), through the use of a large scale exome chip in 20,000
cases of COPD and controls.
Together with the emerging knowledge of genetic determinants of COPD it may contribute to an explanation of the association between COPD related traits and cardiovascular disease.
The Atrial Fibrillation Consortium (AFGen) formed a collaboration to try to identify the genetic basis of Atrial Fibrillation (AF), hoping to lead to new treatments for this common arrythmia.
BWHHS is one of thirty studies contributing globally to performing genetic analyses to identify genetic variants associated with this irregularity of the heart rhythm.